Skip to main content

Table 1 Overall quality of reporting rating using items from the CONSORT Statement (n = 15)

From: Quality of reporting on randomized controlled trials of acupuncture for stroke rehabilitation

Item

Criteria

Description

No. of positive trials

%

95% CI

Cohen’sк coefficient

95% CI

1

“Randomized” in the title or abstract

Study identified as a randomized controlled in the title or abstract

15

100

-

1.00

-

2

Background

Adequate description of the scientific background and explanation of rationale

12

80

57 to 100

0.74

0.50 to 0.98

3

Trial design

Description of trial design (such as parallel, factorial) including allocation ratio

10

67

40 to 94

0.71

0.45 to 1.00

4

Participants

Description of the eligibility criteria for participants

13

87

67 to 100

0.78

0.40 to 1.00

5

Interventions

Details of the interventions intended for each group

11

73

48 to 99

0.82

0.70 to 1.00

6

Outcomes

Definition of primary (and secondary when appropriate) outcome measures

4

27

1 to 52

0.85

0.75 to 0.99

7

Sample size

Description of sample size calculation

2

13

−6 to 33

0.83

0.68 to 1.00

8

Randomization

Description of the method used to generate the random sequence

9

60

32 to 88

0.76

0.60 to 0.99

12

Statistical methods

Description of the statistical methods used to compare groups for primary outcomes, subgroup analyses, or adjusted analyses

11

73

48 to 99

0.73

0.40 to 1.00

13

Flow chart

Details on the flow of participants through each stage of the trials (No. of patients randomly assigned, receiving intended treatment, completing the protocol and analyzed)

5

33

6 to 60

0.84

0.68 to 1.00

14

Recruitment

Dates defining the periods of recruitment and follow-up

6

40

12 to 68

0.65

0.38 to 0.99

15

Baseline data

An outline of baseline demographic and clinical characteristics of each group

14

93

79 to 100

0.68

0.42 to 1.00

17

Outcomes and estimation

For each primary and secondary outcome, a summary of results for each group is given, and the estimated effect size and its precision (e.g. 95% CI)

4

27

1 to 52

0.75

0.52 to 1.00

18

Ancillary analyses

Clear statement of whether subgroup/adjusted analyses were prespecified or exploratory

3

20

−3 to 43

0.68

0.35 to 0.99

19

Harms

Description of all important adverse events in each group

5

33

6 to 60

0.85

0.72 to 1.00